AstraZeneca PLC
AZN
$89.10
$0.490.55%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 58.13B | 56.50B | 54.98B | 54.07B | 51.21B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 58.13B | 56.50B | 54.98B | 54.07B | 51.21B |
| Cost of Revenue | 10.46B | 10.68B | 10.31B | 10.29B | 9.56B |
| Gross Profit | 47.67B | 45.83B | 44.67B | 43.78B | 41.64B |
| SG&A Expenses | 19.84B | 20.00B | 20.08B | 20.14B | 18.77B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -315.00M | -251.00M | -239.00M | -192.00M | -222.00M |
| Total Operating Expenses | 43.69B | 43.73B | 42.95B | 42.72B | 39.90B |
| Operating Income | 14.44B | 12.77B | 12.03B | 11.35B | 11.31B |
| Income Before Tax | 11.44B | 10.02B | 9.29B | 8.69B | 7.92B |
| Income Tax Expenses | 2.04B | 1.72B | 1.51B | 1.65B | 1.42B |
| Earnings from Continuing Operations | 9.40K | 8.30K | 7.78K | 7.04K | 6.50K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -5.00M | -7.00M | -10.00M | -6.00M | -5.00M |
| Net Income | 9.40B | 8.30B | 7.77B | 7.04B | 6.50B |
| EBIT | 14.44B | 12.77B | 12.03B | 11.35B | 11.31B |
| EBITDA | 19.47B | 18.07B | 17.22B | 16.51B | 16.55B |
| EPS Basic | 6.06 | 5.35 | 5.01 | 4.54 | 4.19 |
| Normalized Basic EPS | 5.29 | 4.64 | 4.35 | 4.07 | 4.06 |
| EPS Diluted | 6.02 | 5.31 | 4.97 | 4.50 | 4.15 |
| Normalized Diluted EPS | 5.25 | 4.61 | 4.32 | 4.04 | 4.03 |
| Average Basic Shares Outstanding | 6.20B | 6.20B | 6.20B | 6.20B | 6.20B |
| Average Diluted Shares Outstanding | 6.24B | 6.24B | 6.25B | 6.24B | 6.24B |
| Dividend Per Share | 3.13 | 3.13 | 3.10 | 3.10 | 2.97 |
| Payout Ratio | 52.89% | 59.51% | 63.60% | 65.80% | 71.25% |